Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0255


Precision in targeting breast cancer genome.

George Zografos MD, PhD.

Affiliation: Head of the Breast Unit, Head of 1st Department of Propaedeutic Surgery, University of Athens, Greece.

Tel: +306932524836


Despite rapid progress in translating molecular pathology into positive phase III randomized controlled trials (RCTs) and clinical therapeutic strategy for breast cancer targeted therapy (trastuzumab, trastuzumab-emtansine, lapatinib, palbociclib) relapse rates remain high. Conventional single biopsy and breakthrough multiple solid and liquid biopsies for Next-Generation Sequencing (NGS) analysis provide innovative discoveries in the fields of robust biomarkers and early drug development strategy. However, despite advances in intratumor heterogeneity, circulating genomic subclones diversity and their difference with relapsed and metastatic tumors for each individual patient multiple challenges are emerging. This editorial summarizes latest advances and obstacles to reach Precision Oncology for breast cancer.

(Citation: Gastric & Breast Cancer 2017; 12(1): 1-6)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 25 February 2017